Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis

Aging is associated with an increased incidence of age-related bone diseases. Current diagnostics (e.g., conventional radiology, biochemical markers), because limited in specificity and sensitivity, can distinguish between healthy or osteoporotic subjects but they are unable to discriminate among di...

Full description

Bibliographic Details
Main Authors: Michela Bottani, Giuseppe Banfi, Giovanni Lombardi
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-10-01
Series:Frontiers in Genetics
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fgene.2019.01044/full
_version_ 1818021241680822272
author Michela Bottani
Giuseppe Banfi
Giuseppe Banfi
Giovanni Lombardi
Giovanni Lombardi
author_facet Michela Bottani
Giuseppe Banfi
Giuseppe Banfi
Giovanni Lombardi
Giovanni Lombardi
author_sort Michela Bottani
collection DOAJ
description Aging is associated with an increased incidence of age-related bone diseases. Current diagnostics (e.g., conventional radiology, biochemical markers), because limited in specificity and sensitivity, can distinguish between healthy or osteoporotic subjects but they are unable to discriminate among different underlying causes that lead to the same bone pathological condition (e.g., bone fracture risk). Among recent, more sensitive biomarkers, miRNAs — the non-coding RNAs involved in the epigenetic regulation of gene expression, have emerged as fundamental post-transcriptional modulators of bone development and homeostasis. Each identified miRNA carries out a specific role in osteoblast and osteoclast differentiation and functional pathways (osteomiRs). miRNAs bound to proteins or encapsulated in exosomes and/or microvesicles are released into the bloodstream and biological fluids where they can be detected and measured by highly sensitive and specific methods (e.g., quantitative PCR, next-generation sequencing). As such, miRNAs provide a prompt and easily accessible tool to determine the subject-specific epigenetic environment of a specific condition. Their use as biomarkers opens new frontiers in personalized medicine. While miRNAs circulating levels are lower than those found in the tissue/cell source, their quantification in biological fluids may be strategic in the diagnosis of diseases that affect tissues, such as bone, in which biopsy may be especially challenging. For a biomarker to be valuable in clinical practice and support medical decisions, it must be (easily) measurable, validated by independent studies, and strongly and significantly associated with a disease outcome. Currently, miRNAs analysis does not completely satisfy these criteria, however. Starting from in vitro and in vivo observations describing their biological role in bone cell development and metabolism, this review describes the potential use of bone-associated circulating miRNAs as biomarkers for determining predisposition, onset, and development of osteoporosis and bone fracture risk. Moreover, the review focuses on their clinical relevance and discusses the pre-analytical, analytical, and post-analytical issues in their measurement, which still limits their routine application. Taken together, research and clinical findings may be helpful for creating miRNA-based diagnostic tools in the diagnosis and treatment of bone diseases.
first_indexed 2024-04-14T08:16:19Z
format Article
id doaj.art-2f0d4f0a3664428196ff6db11939c87b
institution Directory Open Access Journal
issn 1664-8021
language English
last_indexed 2024-04-14T08:16:19Z
publishDate 2019-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Genetics
spelling doaj.art-2f0d4f0a3664428196ff6db11939c87b2022-12-22T02:04:24ZengFrontiers Media S.A.Frontiers in Genetics1664-80212019-10-011010.3389/fgene.2019.01044466984Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized DiagnosisMichela Bottani0Giuseppe Banfi1Giuseppe Banfi2Giovanni Lombardi3Giovanni Lombardi4IRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry & Moelcular Biology, Milano, ItalyIRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry & Moelcular Biology, Milano, ItalyVita-Salute San Raffaele University, Milano, ItalyIRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry & Moelcular Biology, Milano, ItalyDepartment of Physiology & Pharmacology, Gdańsk University of Physical Education & Sport, Gdańsk, PolandAging is associated with an increased incidence of age-related bone diseases. Current diagnostics (e.g., conventional radiology, biochemical markers), because limited in specificity and sensitivity, can distinguish between healthy or osteoporotic subjects but they are unable to discriminate among different underlying causes that lead to the same bone pathological condition (e.g., bone fracture risk). Among recent, more sensitive biomarkers, miRNAs — the non-coding RNAs involved in the epigenetic regulation of gene expression, have emerged as fundamental post-transcriptional modulators of bone development and homeostasis. Each identified miRNA carries out a specific role in osteoblast and osteoclast differentiation and functional pathways (osteomiRs). miRNAs bound to proteins or encapsulated in exosomes and/or microvesicles are released into the bloodstream and biological fluids where they can be detected and measured by highly sensitive and specific methods (e.g., quantitative PCR, next-generation sequencing). As such, miRNAs provide a prompt and easily accessible tool to determine the subject-specific epigenetic environment of a specific condition. Their use as biomarkers opens new frontiers in personalized medicine. While miRNAs circulating levels are lower than those found in the tissue/cell source, their quantification in biological fluids may be strategic in the diagnosis of diseases that affect tissues, such as bone, in which biopsy may be especially challenging. For a biomarker to be valuable in clinical practice and support medical decisions, it must be (easily) measurable, validated by independent studies, and strongly and significantly associated with a disease outcome. Currently, miRNAs analysis does not completely satisfy these criteria, however. Starting from in vitro and in vivo observations describing their biological role in bone cell development and metabolism, this review describes the potential use of bone-associated circulating miRNAs as biomarkers for determining predisposition, onset, and development of osteoporosis and bone fracture risk. Moreover, the review focuses on their clinical relevance and discusses the pre-analytical, analytical, and post-analytical issues in their measurement, which still limits their routine application. Taken together, research and clinical findings may be helpful for creating miRNA-based diagnostic tools in the diagnosis and treatment of bone diseases.https://www.frontiersin.org/article/10.3389/fgene.2019.01044/fullbiomarkerscirculating miRNAsmiRNA signatureextra-analytical variabilitysensitivity and specificityosteopenia/osteoporosis
spellingShingle Michela Bottani
Giuseppe Banfi
Giuseppe Banfi
Giovanni Lombardi
Giovanni Lombardi
Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
Frontiers in Genetics
biomarkers
circulating miRNAs
miRNA signature
extra-analytical variability
sensitivity and specificity
osteopenia/osteoporosis
title Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
title_full Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
title_fullStr Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
title_full_unstemmed Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
title_short Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis
title_sort perspectives on mirnas as epigenetic markers in osteoporosis and bone fracture risk a step forward in personalized diagnosis
topic biomarkers
circulating miRNAs
miRNA signature
extra-analytical variability
sensitivity and specificity
osteopenia/osteoporosis
url https://www.frontiersin.org/article/10.3389/fgene.2019.01044/full
work_keys_str_mv AT michelabottani perspectivesonmirnasasepigeneticmarkersinosteoporosisandbonefractureriskastepforwardinpersonalizeddiagnosis
AT giuseppebanfi perspectivesonmirnasasepigeneticmarkersinosteoporosisandbonefractureriskastepforwardinpersonalizeddiagnosis
AT giuseppebanfi perspectivesonmirnasasepigeneticmarkersinosteoporosisandbonefractureriskastepforwardinpersonalizeddiagnosis
AT giovannilombardi perspectivesonmirnasasepigeneticmarkersinosteoporosisandbonefractureriskastepforwardinpersonalizeddiagnosis
AT giovannilombardi perspectivesonmirnasasepigeneticmarkersinosteoporosisandbonefractureriskastepforwardinpersonalizeddiagnosis